Concepts (106)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystitis, Interstitial | 20 | 2020 | 57 | 4.550 |
Why?
|
| Urinary Bladder | 6 | 2019 | 320 | 1.130 |
Why?
|
| Pelvic Pain | 4 | 2017 | 19 | 0.890 |
Why?
|
| Physical Therapy Modalities | 1 | 2019 | 81 | 0.570 |
Why?
|
| Anesthesia | 1 | 2019 | 63 | 0.570 |
Why?
|
| Drug Prescriptions | 1 | 2017 | 54 | 0.510 |
Why?
|
| Analgesics, Opioid | 1 | 2017 | 251 | 0.450 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2012 | 10 | 0.370 |
Why?
|
| Sacrum | 1 | 2012 | 18 | 0.370 |
Why?
|
| Administration, Intravesical | 5 | 2020 | 28 | 0.340 |
Why?
|
| Pain | 1 | 2013 | 303 | 0.340 |
Why?
|
| Practice Guidelines as Topic | 2 | 2013 | 394 | 0.340 |
Why?
|
| Retrospective Studies | 7 | 2020 | 3612 | 0.320 |
Why?
|
| Humans | 23 | 2020 | 32284 | 0.310 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2010 | 63 | 0.300 |
Why?
|
| Middle Aged | 12 | 2020 | 11843 | 0.300 |
Why?
|
| Diagnostic Errors | 2 | 2007 | 38 | 0.290 |
Why?
|
| Female | 14 | 2020 | 19954 | 0.280 |
Why?
|
| Adult | 11 | 2020 | 9263 | 0.270 |
Why?
|
| Urinary Bladder Diseases | 2 | 2020 | 44 | 0.270 |
Why?
|
| Urinary Incontinence | 1 | 2005 | 68 | 0.220 |
Why?
|
| Pentosan Sulfuric Polyester | 4 | 2008 | 5 | 0.200 |
Why?
|
| Aged | 8 | 2019 | 10257 | 0.180 |
Why?
|
| Diagnosis, Differential | 3 | 2007 | 502 | 0.160 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 3896 | 0.150 |
Why?
|
| Endometriosis | 1 | 2020 | 24 | 0.150 |
Why?
|
| Adolescent | 5 | 2019 | 3521 | 0.150 |
Why?
|
| Fibromyalgia | 1 | 2019 | 12 | 0.150 |
Why?
|
| Polyneuropathies | 1 | 2019 | 11 | 0.150 |
Why?
|
| Water | 1 | 2019 | 65 | 0.150 |
Why?
|
| Urinary Diversion | 1 | 2017 | 27 | 0.130 |
Why?
|
| Male | 8 | 2019 | 19434 | 0.130 |
Why?
|
| RNA | 2 | 2016 | 94 | 0.130 |
Why?
|
| Compliance | 1 | 2017 | 14 | 0.130 |
Why?
|
| Syndrome | 2 | 2014 | 66 | 0.120 |
Why?
|
| Cystectomy | 1 | 2017 | 109 | 0.120 |
Why?
|
| Prospective Studies | 2 | 2020 | 2320 | 0.120 |
Why?
|
| Control Groups | 1 | 2016 | 5 | 0.120 |
Why?
|
| Organ Size | 1 | 2017 | 221 | 0.120 |
Why?
|
| Urine | 1 | 2017 | 69 | 0.120 |
Why?
|
| Algorithms | 2 | 2010 | 537 | 0.120 |
Why?
|
| Gene Expression | 1 | 2016 | 345 | 0.110 |
Why?
|
| Lumbosacral Plexus | 2 | 2012 | 7 | 0.110 |
Why?
|
| Young Adult | 2 | 2019 | 2652 | 0.110 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2005 | 65 | 0.110 |
Why?
|
| North Carolina | 1 | 2017 | 1299 | 0.100 |
Why?
|
| Instillation, Drug | 1 | 2013 | 2 | 0.100 |
Why?
|
| Treatment Outcome | 2 | 2020 | 3410 | 0.100 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 1485 | 0.100 |
Why?
|
| Risk Factors | 2 | 2020 | 3938 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 478 | 0.090 |
Why?
|
| Cystoscopy | 2 | 2014 | 27 | 0.080 |
Why?
|
| Diagnostic Techniques, Urological | 1 | 2007 | 4 | 0.060 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2007 | 9 | 0.060 |
Why?
|
| Medical History Taking | 1 | 2007 | 39 | 0.060 |
Why?
|
| Unnecessary Procedures | 1 | 2007 | 16 | 0.060 |
Why?
|
| Patient Satisfaction | 1 | 2008 | 230 | 0.060 |
Why?
|
| Physical Examination | 1 | 2007 | 83 | 0.060 |
Why?
|
| Insurance Claim Review | 1 | 2006 | 26 | 0.060 |
Why?
|
| Mandelic Acids | 1 | 2005 | 2 | 0.060 |
Why?
|
| Efferent Pathways | 1 | 2005 | 10 | 0.060 |
Why?
|
| Phenotype | 2 | 2020 | 619 | 0.060 |
Why?
|
| Afferent Pathways | 1 | 2005 | 40 | 0.060 |
Why?
|
| Muscarinic Antagonists | 1 | 2005 | 38 | 0.060 |
Why?
|
| Prostatitis | 1 | 2005 | 4 | 0.060 |
Why?
|
| Neurotoxins | 1 | 2005 | 16 | 0.060 |
Why?
|
| Diterpenes | 1 | 2005 | 22 | 0.060 |
Why?
|
| Double-Blind Method | 4 | 2008 | 566 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2006 | 773 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2016 | 554 | 0.050 |
Why?
|
| Animals | 1 | 2013 | 8165 | 0.040 |
Why?
|
| Cations | 1 | 2020 | 9 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 98 | 0.040 |
Why?
|
| Anesthetics | 1 | 2019 | 21 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2014 | 411 | 0.040 |
Why?
|
| Cadaver | 1 | 2016 | 151 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2016 | 309 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 2238 | 0.030 |
Why?
|
| Sweden | 1 | 2014 | 16 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2014 | 20 | 0.030 |
Why?
|
| Biopsy | 1 | 2014 | 249 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 960 | 0.020 |
Why?
|
| Glycosylation | 1 | 2011 | 15 | 0.020 |
Why?
|
| Heparinoids | 1 | 2007 | 1 | 0.020 |
Why?
|
| Hydroxyzine | 1 | 2007 | 2 | 0.020 |
Why?
|
| Amitriptyline | 1 | 2007 | 6 | 0.020 |
Why?
|
| Solutions | 1 | 2007 | 39 | 0.020 |
Why?
|
| Glycosaminoglycans | 1 | 2007 | 23 | 0.020 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2007 | 13 | 0.020 |
Why?
|
| Electric Stimulation Therapy | 1 | 2007 | 19 | 0.020 |
Why?
|
| Phytotherapy | 1 | 2007 | 36 | 0.020 |
Why?
|
| Complementary Therapies | 1 | 2007 | 44 | 0.020 |
Why?
|
| Heparin | 1 | 2007 | 65 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2007 | 201 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 709 | 0.020 |
Why?
|
| Anesthetics, Local | 1 | 2007 | 85 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2007 | 293 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 550 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2007 | 248 | 0.010 |
Why?
|
| Placebos | 1 | 2005 | 69 | 0.010 |
Why?
|
| Nausea | 1 | 2005 | 50 | 0.010 |
Why?
|
| Headache | 1 | 2005 | 72 | 0.010 |
Why?
|
| Diarrhea | 1 | 2005 | 72 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2005 | 340 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2005 | 851 | 0.010 |
Why?
|
| Quality of Life | 1 | 2005 | 971 | 0.010 |
Why?
|